Comparative Pharmacology
Head-to-head clinical analysis: VISTARIL versus X TROZINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: VISTARIL versus X TROZINE.
VISTARIL vs X-TROZINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Hydroxyzine is a piperazine derivative antihistamine that acts as a competitive antagonist of histamine H1 receptors, thereby suppressing histamine activity in the subcortical area of the central nervous system. It also has anxiolytic, sedative, antiemetic, and antispasmodic effects.
X-TROZINE acts as a selective serotonin reuptake inhibitor (SSRI) by binding to the serotonin transporter (SERT) and blocking reuptake of serotonin, thereby increasing serotonergic neurotransmission.
Oral: 50-100 mg 4 times daily; IM: 25-100 mg every 4-6 hours as needed.
100 mg orally twice daily
None Documented
None Documented
Terminal elimination half-life: 20-25 hours in adults; prolonged in hepatic impairment or elderly; steady-state achieved in ~4-5 days.
Terminal elimination half-life is 12-15 hours in healthy adults; prolonged to 24-36 hours in severe renal impairment (CrCl <30 mL/min), requiring dose adjustment.
Primarily hepatic metabolism; <1% excreted unchanged in urine; biliary/fecal elimination of metabolites accounts for approximately 50-60% of total clearance.
Renal excretion accounts for 60-70% of total clearance, predominantly as unchanged drug. Biliary/fecal elimination constitutes 20-30% via P-glycoprotein-mediated transport. Minor metabolism (<10%) via CYP3A4.
Category C
Category C
Antihistamine
Antihistamine